CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
C Ritchie, AH Noel‐Storr… - Cochrane Database …, 2017 - cochranelibrary.com
Background Research suggests that measurable change in cerebrospinal fluid (CSF)
biomarkers occurs years in advance of the onset of clinical symptoms (Beckett 2010). In this …
biomarkers occurs years in advance of the onset of clinical symptoms (Beckett 2010). In this …
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development …
The use of biomarkers has been proposed for diagnosing Alzheimer's disease in recent
criteria, but some biomarkers have not been sufficiently investigated to justify their routine …
criteria, but some biomarkers have not been sufficiently investigated to justify their routine …
Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
TA Pascoal, S Mathotaarachchi, S Mohades… - Molecular …, 2017 - nature.com
This study was designed to test the interaction between amyloid-β and tau proteins as a
determinant of metabolic decline in preclinical Alzheimer's disease (AD). We assessed 120 …
determinant of metabolic decline in preclinical Alzheimer's disease (AD). We assessed 120 …
The cerebrospinal fluid Aβ 1–42/Aβ 1–40 ratio improves concordance with amyloid-PET for diagnosing Alzheimer's disease in a clinical setting
E Niemantsverdriet, J Ottoy, C Somers… - Journal of …, 2017 - content.iospress.com
Background: Evidence suggests that the concordance between amyloid-PET and
cerebrospinal fluid (CSF) amyloid-ß (Aß) increases when the CSF Aß1–42/Aß1–40 ratio is …
cerebrospinal fluid (CSF) amyloid-ß (Aß) increases when the CSF Aß1–42/Aß1–40 ratio is …
Sembragiline: a novel, selective monoamine oxidase type B inhibitor for the treatment of Alzheimer's disease
E Borroni, B Bohrmann, F Grueninger, E Prinssen… - … of Pharmacology and …, 2017 - ASPET
Monoamine oxidase B (MAO-B) has been implicated in the pathogenesis of Alzheimer's
disease (AD) and other neurodegenerative disorders. Increased MAO-B expression in …
disease (AD) and other neurodegenerative disorders. Increased MAO-B expression in …
[图书][B] Molecular imaging of tau in the pathological cascade of Alzheimer's disease
K Chiotis - 2017 - openarchive.ki.se
The pathology of Alzheimer's disease (AD) is characterised by the misfolding and
aggregation of amyloid-β (Aβ) into extracellular plaques and aggregation of tau into …
aggregation of amyloid-β (Aβ) into extracellular plaques and aggregation of tau into …
[PDF][PDF] Nicholas James Ashton
AB SIGNATURE, NA BURDEN, AN EARLY - kclpure.kcl.ac.uk
Alzheimers disease (AD) biomarkers that can detect and track disease progression at its
earliest stages to aid the critical search for a disease modifying therapy is much needed …
earliest stages to aid the critical search for a disease modifying therapy is much needed …